Provided by Tiger Trade Technology Pte. Ltd.

Incyte

92.23
+1.611.78%
Post-market: 92.600.3700+0.40%17:47 EDT
Volume:1.06M
Turnover:97.47M
Market Cap:18.36B
PE:14.39
High:93.83
Open:91.00
Low:91.00
Close:90.62
52wk High:112.29
52wk Low:53.56
Shares:199.01M
Float Shares:163.04M
Volume Ratio:0.51
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.41
EPS(LYR):6.41
ROE:29.87%
ROA:13.57%
PB:3.55
PE(LYR):14.39

Loading ...

Wells Fargo Downgrades Incyte to Equalweight From Overweight, Adjusts PT to $107 From $116

MT Newswires Live
·
Jan 20

Wells downgrades Incyte to Equal Weight on lack of catalysts

TIPRANKS
·
Jan 20

Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis

TIPRANKS
·
Jan 17

Guggenheim Adjusts Price Target on Incyte to $130 From $125, Maintains Buy Rating

MT Newswires Live
·
Jan 16

FACTBOX-Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Reuters
·
Jan 16

Incyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating

TIPRANKS
·
Jan 15

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jan 15

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jan 14

Balancing Near‑Term Strength and Post‑Jakafi Uncertainty: Why Incyte Merits a Hold Rating

TIPRANKS
·
Jan 13

Incyte : TD Cowen Raises Target Price to $128 From $101

THOMSON REUTERS
·
Jan 13

Incyte: Diversifying Beyond Jakafi With a High-Value Late-Stage Pipeline and Disciplined Growth Strategy

TIPRANKS
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH)

TIPRANKS
·
Jan 13

Incyte Unveils Strategic Growth Plan Focused on Hematology, Oncology, and Autoimmunity

Reuters
·
Jan 13

Incyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors

TIPRANKS
·
Jan 10

Top Incyte Executive Makes Major Move With Fresh Stock Sale

TIPRANKS
·
Jan 09

Incyte EVP Head of US Oncology Issa Mohamed Khairie Reports Disposal of Common Shares

Reuters
·
Jan 09

RBC Raises Price Target on Incyte to $92 From $84, Keeps Sector Perform Rating

MT Newswires Live
·
Jan 08

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jan 08

Incyte EVP & Chief Medical Officer Steven H. Stein Reports Sale of Common Shares

Reuters
·
Jan 08

Incyte on Track for Highest Close Since October 2017 -- Data Talk

Dow Jones
·
Jan 08